This work examines the requirements for patentability in the context of biotechnology, with a special focus on non obviousness. Reviewing the relevant case law, it analyses thoroughly non obviousness as applied to biotechnology molecular products. It first offers a typology of recombinant inventions, useful in determining ultimate non obviousness and patentability. Three categories of recombinant products are distinguished. "Translation" inventions, obtained by entering a known molecular information into a known process. "Molecular modification" products, obtained by modifying prior art molecules. "Combination" inventions, obtained by combining several known functional molecular units. Recognizing that many "translation" inventions are at risk of being considered obvious upon maturation of the underlying technology, the author examines possible alternatives for protection.
Note
Price : 51.52; Inv.# CH52902; Date 11/08/98; Supplier : CroftHouse, UK; Recd 25/08/98; Contents : 1. Patent law primer; 2. Recombinant products and the standard for obviousness : a typology; 3. In re Deuel : the Federal circuit and "translation" DNAs; 4. Generalization of a concept : other biotechnology products are "translation" inventions; 5. Consequences and remedies;. "Originally presented as the author's thesis presented at Stanford University School of Law for the J.S.D degree"--Preface. Omslagtitel: Patenting the recombinant products of biotechnology and other molecules. Umschlagtitel: Patenting the recombinant products of biotechnology and other molecules.
Bibliography, etc. Note
Includes bibliographical references (pages 167-172) and index.